Terminology Service for NFDI4Health

Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes

Go to external page http://purl.obolibrary.org/obo/NCIT_C71748


Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. [ ]

Term info

Label

Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes

Synonyms
  • Anti-p53 TCR-Transduced PBL
  • Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes
  • Autologous Anti-gp100:154-162 TCR Gene-Engineered PBL
Subsets

NCIT_C128784

Legacy Concept Name

Autologous_Anti-gp100_154-162_TCR_Gene-engineered_PBL

NCI META CUI

CL376139

Preferred Name

Autologous Anti-gp100:154-162 T-Cell Receptor Gene-Engineered Peripheral Blood Lymphocytes

Semantic Type

Pharmacologic Substance, Cell

code

C71748